ASRS 2023: Health disparities in lapses in diabetic retinopathy care

News
Video

Cindy Cai, MD, shared insights from her presentation from ASRS 2023, "Health disparities in lapses in diabetic retinopathy care," with Sheryl Stevenson, our Group Editorial Director.

Cindy Cai, MD, shared insights from her presentation from ASRS 2023, titled "Health disparities in lapses in diabetic retinopathy care," with Sheryl Stevenson, our Group Editorial Director.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Sheryl Stevenson:

We're joined today by Dr Cindy Cai, who will be presenting at this year's ASRS meeting in Seattle. Welcome to you, Dr Cai.

Cindy Cai, MD:

Thanks, Sheryl.

Sheryl Stevenson:

We're really curious to hear more about your talk regarding health disparities in lapses in diabetic retinopathy care. That sounds like such a timely topic right now. Can you tell us more about your talk?

Cindy Cai, MD:

Yeah, thanks so much for that question. As you know, Sheryl, diabetic retinopathy is the ophthalmic manifestation of diabetes. Even though we have great preventive strategies and treatments for diabetic retinopathy, it's still the leading cause of blindness among the working age adults in the US. That's because a lot of times our patients with diabetes aren't returning to eye care as recommended by their provider, [and] they have what we call a lapse in their diabetic retinopathy care.

So in our study, we looked to see whether there were differences in rates and lapses in diabetic retinopathy care by different racial and ethnic groups. We included about 40,000 patients with diabetes who had come through the Wilmer Eye Institute for diabetic retinopathy screening or treatment, and found that overall, about three-quarters of patients have a lapse in diabetic retinopathy care at some point during the first 2 years of follow up. These rates were different by race and ethnic groups, whereby our non-Hispanic black patients and Hispanic patients had a much higher chance for having a lapse in diabetic retinopathy care as compared to otherwise similar non-Hispanic white patients. This was a statistically significant finding, and obviously very important.

Of course, identifying these health disparities by race and ethnicity is just the first step. Ultimately, we want to develop interventions and strategies to eliminate the health disparities that we're seeing. So, we're in the process of taking this methodology that we've developed to identify lapses in diabetic retinopathy care, and deploying it in real time in our electronic health record, so that we can identify lapses in care as they're happening and provide additional resources for patients who might need the most support. So, this is ongoing work and I encourage everyone to stay tuned.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.